Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allergovit 6-grasses EEC Validation Study
NCT02297490Phase 2Terminated
- Sponsor
- Allergopharma
- Start
- Jan 2014
- Primary completion
- Nov 2014
- Modality
- Peptides, Peptide-based Cancer Vaccines, Allergy Immunotherapy
- Countries
- 1
01
Overview
A Phase 2 trial of Allergovit in allergic rhinoconjunctivitis (ARC), sponsored by Allergopharma. Started Jan 2014; status: terminated.
02
Drugs
Allergovit
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT02297490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02297490.